If you have used Depo-Provera and have been hearing about a possible connection to brain tumors, it is reasonable to want to understand what the science actually says and what is happening in the courts.

The research is real. The litigation is real. The U.S. warning label changed in December 2025. And a federal court process is moving forward right now that may be directly relevant to your situation.

What the Medical Research Shows

The concern about Depo-Provera is grounded in two significant studies published in major peer-reviewed journals.

In March 2024, the British Medical Journal published a French national case-control study by Roland and colleagues examining 18,061 women who had intracranial surgery for meningioma and 90,305 matched controls without the condition. The researchers found that prolonged use of medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera, was associated with approximately a 5.55-fold increased risk of meningioma requiring surgery. Notably, the same study found no similar association for levonorgestrel IUDs or commonly used oral progesterone-only pills. The elevated risk was specific to long-term injectable use.

In September 2025, JAMA (Journal of American Medical Association) Neurology published a U.S.-based analysis using Medicaid data, led by Xiao and colleagues. The U.S. study found a smaller but still meaningful association, approximately 2.43 times the risk in long-term users. Because Depo-Provera is far more widely used in the United States than in France, the U.S. analysis drew on a substantially larger exposed population.

The two studies measure slightly different populations, but they point in the same direction.

A meningioma is a tumor that develops in the layers of tissue covering the brain and spinal cord. Most are slow-growing and not cancerous, but they can press on the brain and cause real harm. Symptoms may include headaches, vision changes, hearing changes, vertigo, seizures, or changes in mood and thinking. Treatment often involves surgery, sometimes followed by radiation, and ongoing imaging to monitor for recurrence.

The absolute risk of meningioma for any individual woman remains low, even with the elevated relative risk shown in these studies. Researchers and clinicians have been careful to note this. The reason it still matters is that millions of women have used Depo-Provera, and the impact on patients who are affected can be substantial.

When the Manufacturer May Have Known, and What the Label Said

Depo-Provera was approved by the U.S. Food and Drug Administration (FDA) in 1992. Plaintiffs in the current litigation allege that Pfizer Inc. and its predecessors knew, or should have known, about the meningioma risk for years through case reports, surgical literature, and emerging epidemiological research, but did not warn American patients.

The European product label had carried meningioma-related warnings for years. The U.S. label did not.

That changed on December 12, 2025, when the FDA approved updated labeling for both Depo-Provera CI and Depo-SubQ Provera 104, adding a meningioma warning for the first time. The new label states that cases of meningioma have been reported following repeated administration of MPA, primarily with long-term use.

That label change is precisely what plaintiffs argue should have happened years earlier.

The Lawsuits and the Federal Multidistrict Litigation

A federal multidistrict litigation (MDL), MDL No. 3140, was established on February 7, 2025, by the U.S. Judicial Panel on Multidistrict Litigation. All federal Depo-Provera meningioma lawsuits are being consolidated before U.S. District Judge M. Casey Rodgers in the Northern District of Florida. Judge Rodgers previously presided over the 3M Combat Arms Earplug MDL, one of the largest mass tort proceedings in U.S. history.

As of June 2026, more than 5,500 cases have been filed in the MDL. The litigation has grown at a remarkable pace, expanding from approximately 78 cases in March 2025 to over 3,000 by March 2026, a nearly 4,000 percent increase in one year.

Three procedural milestones are worth understanding.

The first is the general causation hearing. Originally scheduled for late May 2026, the Daubert hearing on plaintiffs’ general causation experts has been rescheduled to June 24-26, 2026. Judge Rodgers will decide whether the plaintiffs’ scientific experts may testify at trial. If the experts pass, the litigation moves forward on its current track. If they do not, plaintiffs may face a serious setback. This is one of the most consequential phases of any pharmaceutical injury case.

The second is the bellwether trial. Five pilot cases have been selected as early test trials. The first, Blonski v. Pfizer, is scheduled to begin December 7, 2026. Bellwether trials are not binding on other plaintiffs, but they give both sides a sense of how juries respond to the evidence, and they often drive settlement negotiations across the broader litigation.

The third is the federal preemption dispute. Pfizer argues that because the FDA rejected its proposed meningioma label change in 2024, federal law preempts state failure-to-warn claims. Plaintiffs counter that Pfizer’s proposed language was inadequate and that the company had other available paths to strengthen the warning. The court’s ruling on this question may affect every case in the MDL. It has not been decided.

Anyone reading this honestly should understand: this litigation is moving, but it has not been resolved. That is normal for a proceeding of this scale at this stage.

Who May Qualify to File

You may qualify to pursue a Depo-Provera claim if all of the following apply. You received Depo-Provera injections, including the standard Depo-Provera CI, the Depo-SubQ Provera 104 formulation, or generic MPA injections. You used the medication for a meaningful period of time, typically at least one year, though the scientific link is clearest with longer exposure. You were later diagnosed with a meningioma, usually confirmed by MRI imaging or surgical pathology. And you can produce medical records showing both the Depo-Provera prescriptions and the meningioma diagnosis.

You may still qualify if you took the generic rather than the brand-name product, if your meningioma was found incidentally during imaging for another reason, or if the tumor has been documented but surgery has not yet been performed.

You do not need to have filed an FDA adverse event report. You do not need an underlying criminal case. You do not need to have made up your mind about whether to file before speaking with an attorney.

What Filing Actually Requires

The practical picture is straightforward. You will need medical records showing your Depo-Provera use, including dates, dosages, and the prescribing clinic or physician; imaging and pathology reports confirming the meningioma; treatment records including any surgery, radiation, ongoing monitoring, and medications; and a general timeline of your symptoms, diagnosis, and treatment.

An attorney who handles MDL cases will evaluate whether your records meet the criteria, at no charge to you. The case is taken on contingency, which means you pay nothing unless the case recovers compensation for you.

Frequently Asked Questions Regarding Depo-Provera

Q: Do I have to live near the MDL court to file?
A: No. Your case may be filed in your home state and then transferred into the MDL. You generally will not need to travel to Florida.

Q: Is there a deadline to file?
A: Yes. Statutes of limitations vary by state, and the clock often begins from your diagnosis or from the date you reasonably could have connected the meningioma to Depo-Provera. Do not wait to speak with an attorney about your specific timing.

Q: Will I have to testify in court?
A: Most MDL cases resolve through settlement after bellwether trial outcomes. Most individual plaintiffs never set foot in a courtroom. If your case does proceed to trial, your attorney will prepare you well in advance.

Q: What does the lawsuit actually seek?
A: Compensation for past and future medical expenses, lost income, pain and suffering, and the cost of ongoing care including monitoring for tumor recurrence.

Q: Should I stop using Depo-Provera?
A: This is a medical decision, not a legal one. Talk to your doctor. Your physician is the right person to help you weigh your contraceptive options. Your attorney can help with the civil claim.

How Constant Legal Group Can Help

If you received Depo-Provera and were later diagnosed with a meningioma or other brain tumor, you may be entitled to compensation. Constant Legal Group (CLG) handles Depo-Provera mass tort cases nationwide. Every consultation is free, confidential, and carries no obligation. There is no upfront cost. We only get paid if we recover compensation for you.

Call us at 855-906-2561

Last updated June 12, 2026. This litigation is moving quickly. Key rulings on general causation and federal preemption are expected in the summer of 2026. This article is for informational purposes only and does not constitute legal advice. Contact Constant Legal Group for a confidential evaluation specific to your circumstances. Case outcomes vary significantly based on the specific facts of each case, jurisdiction, and applicable law.